Clinic
Arnot Ogden Medical Center
Arnot Ogden Medical Center was paid $60.80M by Medicaid between Jun 2018 and Dec 2024, across 431 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 18% of everything it billed.
33Billing provider infoARNOT OGDEN MEDICAL CENTER
ELMIRA, NY 14905
ELMIRA, NY 14905
33aNPI1083605661assigned 11/02/2005
33bProvider typeEnd-Stage Renal Disease (ESRD) Treatment Clinic/Center
28Total paid$60.80M
24GClaims1,294,887
24DCodes billed431
24AFirst – last monthJun 2018 – Dec 2024
Compared with peers
Next to other End-Stage Renal Disease (ESRD) Treatment Clinic/Center providers in New York
Rank by total paid#2 of 231
Median peer was paid$774K
This provider vs. median79×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,581 | $333K | |
| 2019 | 90,177 | $4.06M | |
| 2020 | 208,902 | $9.45M | |
| 2021 | 243,938 | $11.50M | |
| 2022 | 264,227 | $12.32M | |
| 2023 | 267,834 | $12.88M | |
| 2024incomplete | 211,228 | $10.25M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 18% | 116,303 | 104,941 | $10.99M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 14% | 95,054 | 86,390 | $8.50M |
| G0378 | Hospital observation service, per hour | 9.3% | 5,212 | 2,928 | $5.67M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.3% | 34,960 | 32,676 | $3.86M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.1% | 41,402 | 38,838 | $3.69M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.0% | 26,565 | 9,251 | $1.83M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 19,239 | 18,478 | $1.54M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.3% | 20,940 | 19,525 | $1.42M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.0% | 10,505 | 9,803 | $1.23M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 4,899 | 4,208 | $1.05M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.6% | 2,514 | 1,238 | $970K |
| 80053 | Comprehensive metabolic panel | 1.5% | 51,417 | 45,951 | $933K |
419 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 3,483 | $831K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 5,019 | $795K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 2,810 | $714K |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 96,738 | $707K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.1% | 7,362 | $690K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.0% | 6,484 | $625K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 5,926 | $591K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 5,957 | $519K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 10,707 | $515K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 4,917 | $513K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 4,360 | $484K |
| 87631 | <1% | 7,588 | $448K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,946 | $378K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 3,281 | $359K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,359 | $350K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 11,432 | $343K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 3,067 | $343K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 14,989 | $332K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 436 | $292K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 8,160 | $283K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,009 | $273K |
| 97161 | <1% | 2,846 | $242K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,998 | $236K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 2,160 | $218K |
| 17110 | <1% | 985 | $212K | |
| 20610 | <1% | 915 | $210K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 349 | $188K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,518 | $185K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,576 | $169K |
| 97162 | <1% | 1,595 | $169K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,836 | $160K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,673 | $153K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,598 | $151K |
| 76942 | <1% | 842 | $139K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,520 | $135K |
| 12001 | <1% | 352 | $134K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,517 | $133K |
| 90686 | <1% | 5,720 | $133K | |
| 96161 | <1% | 4,530 | $126K | |
| 80061 | Lipid panel | <1% | 16,664 | $125K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 20,473 | $123K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,872 | $119K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 581 | $117K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 406 | $115K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,370 | $111K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,881 | $111K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 56,018 | $111K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 371 | $106K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 14,536 | $105K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,729 | $99K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 314 | $93K |
| 59025 | Fetal non-stress test | <1% | 543 | $92K |
| 97113 | <1% | 1,032 | $91K | |
| 99205 | Prolong outpt/office vis | <1% | 849 | $90K |
| 96415 | <1% | 266 | $90K | |
| 11102 | <1% | 204 | $87K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,219 | $85K |
| 27096 | <1% | 153 | $84K | |
| 87536 | <1% | 1,024 | $81K | |
| 92551 | <1% | 1,558 | $80K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 797 | $80K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 10,515 | $79K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,720 | $74K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 3,339 | $71K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 545 | $65K |
| 98926 | <1% | 2,303 | $63K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 890 | $60K |
| 82607 | <1% | 6,389 | $60K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,244 | $60K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 354 | $55K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,963 | $53K |
| 76775 | <1% | 1,325 | $53K | |
| 90670 | <1% | 2,653 | $51K | |
| 93971 | <1% | 1,006 | $49K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 170 | $48K |
| 90715 | <1% | 1,829 | $48K | |
| 97597 | <1% | 120 | $47K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,602 | $47K |
| 84439 | <1% | 6,755 | $46K | |
| 86850 | <1% | 3,010 | $45K | |
| 88342 | <1% | 893 | $45K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 792 | $44K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,849 | $43K |
| 82746 | <1% | 4,683 | $43K | |
| 90680 | <1% | 2,155 | $42K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 395 | $41K |
| 97165 | <1% | 593 | $38K | |
| 86901 | <1% | 3,275 | $35K | |
| 82728 | <1% | 3,590 | $35K | |
| 83655 | <1% | 2,459 | $35K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 864 | $34K |
| 62323 | <1% | 83 | $34K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 395 | $32K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 122 | $32K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 923 | $31K |
| 87660 | <1% | 3,929 | $30K | |
| 90633 | <1% | 1,546 | $30K | |
| 83880 | <1% | 995 | $30K | |
| 90698 | <1% | 1,661 | $29K | |
| 86360 | <1% | 863 | $29K | |
| 29581 | <1% | 634 | $29K | |
| 93320 | <1% | 807 | $29K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 361 | $28K |
| 86900 | <1% | 3,275 | $28K | |
| 87340 | <1% | 3,554 | $28K | |
| 86762 | <1% | 2,144 | $28K | |
| 86480 | <1% | 469 | $27K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 299 | $27K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 379 | $27K |
| 86803 | <1% | 3,618 | $26K | |
| 76536 | <1% | 1,144 | $25K | |
| 87480 | <1% | 3,411 | $23K | |
| 90723 | <1% | 984 | $22K | |
| 90647 | <1% | 992 | $22K | |
| 87510 | <1% | 3,303 | $21K | |
| 93975 | <1% | 66 | $21K | |
| 83735 | <1% | 11,382 | $20K | |
| 90677 | <1% | 679 | $20K | |
| 93017 | <1% | 338 | $20K | |
| 84403 | <1% | 877 | $20K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 338 | $19K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,837 | $19K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 979 | $19K |
| 84153 | <1% | 1,287 | $19K | |
| 76642 | <1% | 962 | $19K | |
| 98925 | <1% | 911 | $19K | |
| 99442 | <1% | 179 | $19K | |
| 80076 | <1% | 1,656 | $19K | |
| 0352U | <1% | 629 | $18K | |
| 97035 | <1% | 892 | $18K | |
| 90688 | <1% | 633 | $17K | |
| 84702 | <1% | 2,477 | $17K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 25 | $17K |
| 71271 | <1% | 626 | $16K | |
| 86359 | <1% | 861 | $16K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 577 | $16K |
| 94060 | <1% | 385 | $15K | |
| 90744 | <1% | 865 | $15K | |
| 76937 | <1% | 94 | $15K | |
| 82570 | <1% | 4,236 | $15K | |
| 83540 | <1% | 4,067 | $15K | |
| 86618 | <1% | 1,430 | $15K | |
| 84481 | <1% | 2,110 | $15K | |
| 90707 | <1% | 684 | $14K | |
| 88304 | <1% | 400 | $14K | |
| 87077 | <1% | 4,031 | $14K | |
| 83550 | <1% | 3,869 | $14K | |
| 82043 | <1% | 3,614 | $13K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,781 | $13K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,621 | $13K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 240 | $13K |
| 11045 | <1% | 21 | $13K | |
| 82803 | <1% | 428 | $12K | |
| 83001 | <1% | 728 | $12K | |
| 83615 | <1% | 3,861 | $11K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 121 | $11K |
| 93325 | <1% | 806 | $11K | |
| 81001 | <1% | 12,544 | $11K | |
| 90651 | <1% | 271 | $11K | |
| 90656 | <1% | 569 | $11K | |
| 81025 | <1% | 3,311 | $11K | |
| 85610 | <1% | 3,220 | $10K | |
| 93298 | <1% | 680 | $10K | |
| 90716 | <1% | 506 | $10K | |
| 73221 | <1% | 37 | $10K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 24 | $10K |
| 86376 | <1% | 857 | $10K | |
| 86592 | <1% | 4,882 | $10K | |
| 87186 | <1% | 3,575 | $9K | |
| 10060 | <1% | 37 | $9K | |
| 83970 | <1% | 236 | $9K | |
| 82670 | <1% | 386 | $9K | |
| 86800 | <1% | 850 | $9K | |
| 90734 | <1% | 393 | $9K | |
| 82947 | <1% | 2,547 | $9K | |
| 87070 | <1% | 2,814 | $9K | |
| 90710 | <1% | 430 | $9K | |
| 82950 | <1% | 1,680 | $8K | |
| 83525 | <1% | 833 | $8K | |
| 83002 | <1% | 539 | $8K | |
| 93970 | <1% | 25 | $8K | |
| 86705 | <1% | 1,440 | $8K | |
| 82977 | <1% | 2,033 | $8K | |
| 92526 | <1% | 79 | $8K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 188 | $7K |
| 82533 | <1% | 550 | $7K | |
| 90696 | <1% | 310 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,596 | $6K |
| 71250 | <1% | 66 | $6K | |
| 82805 | <1% | 216 | $6K | |
| 99221 | <1% | 82 | $6K | |
| 36591 | <1% | 290 | $6K | |
| 91322 | <1% | 81 | $6K | |
| 77066 | Tomosynthesis, mammo | <1% | 100 | $6K |
| 85730 | <1% | 2,151 | $6K | |
| 94726 | <1% | 432 | $6K | |
| 86140 | <1% | 2,750 | $5K | |
| 99443 | <1% | 48 | $5K | |
| 12011 | <1% | 14 | $5K | |
| 86709 | <1% | 989 | $5K | |
| 84100 | <1% | 1,228 | $5K | |
| 85027 | <1% | 2,236 | $5K | |
| 73630 | <1% | 2,361 | $5K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,146 | $5K |
| 72100 | <1% | 935 | $5K | |
| 97116 | <1% | 137 | $5K | |
| 64615 | <1% | 13 | $5K | |
| 87641 | <1% | 182 | $5K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 50 | $5K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 44 | $5K |
| 73030 | <1% | 1,591 | $4K | |
| 99460 | <1% | 57 | $4K | |
| 86225 | <1% | 1,253 | $4K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 25 | $4K |
| 74183 | <1% | 14 | $4K | |
| 86666 | <1% | 262 | $4K | |
| 94729 | <1% | 477 | $4K | |
| 81003 | <1% | 7,306 | $4K | |
| 86038 | <1% | 1,161 | $4K | |
| 84146 | <1% | 225 | $4K | |
| 93225 | <1% | 153 | $4K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 80 | $4K |
| 99223 | Prolong inpt eval add15 m | <1% | 25 | $3K |
| 90700 | <1% | 133 | $3K | |
| 84460 | <1% | 1,055 | $3K | |
| 84550 | <1% | 1,122 | $3K | |
| 82784 | <1% | 322 | $3K | |
| 85651 | <1% | 2,379 | $3K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 151 | $3K |
| 97166 | <1% | 37 | $3K | |
| 83690 | <1% | 7,977 | $3K | |
| 95806 | <1% | 73 | $3K | |
| 86003 | <1% | 64 | $3K | |
| 81596 | <1% | 68 | $3K | |
| 77080 | <1% | 64 | $3K | |
| 86431 | <1% | 751 | $3K | |
| 73564 | <1% | 436 | $3K | |
| 82247 | <1% | 945 | $3K | |
| 99441 | <1% | 32 | $3K | |
| 84703 | <1% | 6,241 | $3K | |
| 90732 | <1% | 59 | $3K | |
| 93297 | <1% | 238 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 44 | $2K |
| 70486 | <1% | 55 | $2K | |
| 17000 | <1% | 12 | $2K | |
| 76882 | <1% | 95 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,045 | $2K |
| 86580 | <1% | 473 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,001 | $2K |
| 73130 | <1% | 1,548 | $2K | |
| 73610 | <1% | 1,647 | $2K | |
| 84112 | <1% | 70 | $2K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 48 | $2K |
| 74178 | <1% | 12 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 54 | $2K |
| 84450 | <1% | 647 | $2K | |
| 85045 | <1% | 1,118 | $2K | |
| 98927 | <1% | 79 | $2K | |
| Q3014 | Telehealth originating site facility fee | <1% | 148 | $2K |
| 76000 | <1% | 13 | $2K | |
| 87486 | <1% | 103 | $2K | |
| 87581 | <1% | 103 | $2K | |
| 85018 | <1% | 2,199 | $2K | |
| 87468 | <1% | 86 | $2K | |
| 73562 | <1% | 620 | $2K | |
| 87469 | <1% | 86 | $2K | |
| 87484 | <1% | 86 | $2K | |
| 87478 | <1% | 86 | $2K | |
| 82248 | <1% | 446 | $2K | |
| 73502 | <1% | 575 | $2K | |
| 85652 | <1% | 1,703 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,528 | $2K |
| 73110 | <1% | 795 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 921 | $2K |
| 84156 | <1% | 637 | $1K | |
| 84402 | <1% | 63 | $1K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 13 | $1K |
| 86706 | <1% | 271 | $1K | |
| 73560 | <1% | 568 | $1K | |
| 74018 | <1% | 702 | $1K | |
| 85007 | <1% | 1,523 | $1K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 13 | $1K |
| 84484 | <1% | 5,458 | $1K | |
| 99381 | <1% | 14 | $1K | |
| 87640 | <1% | 189 | $1K | |
| 80178 | <1% | 243 | $1K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 63 | $1K |
| 86696 | <1% | 74 | $1K | |
| 84590 | <1% | 106 | $966.95 | |
| 84144 | <1% | 50 | $961.79 | |
| 80164 | <1% | 121 | $955.63 | |
| 87081 | <1% | 392 | $850.41 | |
| 85379 | <1% | 1,147 | $833.07 | |
| 90381 | <1% | 37 | $803.20 | |
| 76857 | <1% | 41 | $796.59 | |
| C1769 | Guide wire | <1% | 544 | $773.47 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,118 | $769.30 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 436 | $732.29 |
| 90694 | <1% | 78 | $730.86 | |
| 88307 | <1% | 12 | $721.92 | |
| 84480 | <1% | 173 | $716.28 | |
| 86765 | <1% | 64 | $713.90 | |
| 87040 | <1% | 987 | $703.87 | |
| 11721 | <1% | 61 | $630.81 | |
| 88341 | <1% | 35 | $630.10 | |
| 95911 | <1% | 12 | $611.33 | |
| 93242 | <1% | 100 | $609.55 | |
| 95886 | <1% | 39 | $560.61 | |
| 82150 | <1% | 185 | $536.19 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 40 | $530.71 |
| 82550 | <1% | 249 | $496.27 | |
| 84425 | <1% | 41 | $480.00 | |
| 93295 | <1% | 25 | $459.71 | |
| 36416 | <1% | 17 | $445.50 | |
| 82565 | <1% | 167 | $434.35 | |
| 84132 | <1% | 612 | $418.68 | |
| 72040 | <1% | 75 | $417.00 | |
| 90480 | <1% | 95 | $370.00 | |
| 95885 | <1% | 38 | $368.31 | |
| 80047 | <1% | 17 | $361.48 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 6,490 | $358.63 |
| 84520 | <1% | 157 | $319.40 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 16 | $309.64 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 13 | $290.63 |
| 86308 | <1% | 149 | $290.23 | |
| 73080 | <1% | 213 | $286.09 | |
| 87075 | <1% | 109 | $275.62 | |
| G0008 | Administration of influenza virus vaccine | <1% | 117 | $267.94 |
| 86753 | <1% | 52 | $265.24 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 39 | $264.89 |
| 73590 | <1% | 113 | $228.56 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,906 | $228.30 |
| 83605 | <1% | 1,242 | $203.26 | |
| 82172 | <1% | 15 | $197.45 | |
| 73100 | <1% | 44 | $178.58 | |
| 83010 | <1% | 17 | $176.79 | |
| 93270 | <1% | 24 | $172.71 | |
| 81002 | <1% | 2,959 | $161.76 | |
| 84436 | <1% | 53 | $159.60 | |
| 94664 | <1% | 1,379 | $154.37 | |
| 84165 | <1% | 41 | $147.50 | |
| 82375 | <1% | 144 | $142.71 | |
| 73090 | <1% | 130 | $138.76 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,340 | $118.32 |
| 74019 | <1% | 42 | $117.00 | |
| 82077 | <1% | 1,742 | $113.73 | |
| 86141 | <1% | 12 | $102.50 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 612 | $101.42 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 7,097 | $91.40 |
| A9270 | Non-covered item or service | <1% | 25,962 | $90.69 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,753 | $87.09 |
| 73600 | <1% | 14 | $84.68 | |
| 87045 | <1% | 13 | $82.06 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,606 | $76.43 |
| 80143 | <1% | 1,529 | $76.38 | |
| 82378 | <1% | 13 | $75.84 | |
| 94010 | <1% | 13 | $68.65 | |
| 83050 | <1% | 146 | $66.86 | |
| 73120 | <1% | 13 | $66.66 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,577 | $61.71 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,009 | $60.69 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,023 | $55.35 |
| 80177 | <1% | 12 | $52.50 | |
| 80179 | <1% | 1,497 | $51.44 | |
| 83721 | <1% | 135 | $49.22 | |
| 90461 | <1% | 4,416 | $45.28 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,912 | $44.30 |
| 85014 | <1% | 43 | $44.07 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,429 | $43.86 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 327 | $40.32 |
| 72050 | <1% | 13 | $36.00 | |
| 72070 | <1% | 12 | $36.00 | |
| 82105 | <1% | 12 | $32.71 | |
| 71101 | <1% | 14 | $31.50 | |
| 84155 | <1% | 28 | $29.36 | |
| 82140 | <1% | 34 | $29.14 | |
| 99173 | <1% | 169 | $28.98 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,219 | $24.22 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 425 | $23.48 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,432 | $22.53 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 961 | $22.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,206 | $21.31 |
| 96376 | <1% | 631 | $18.47 | |
| 99152 | <1% | 14 | $18.24 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 480 | $17.67 |
| 82330 | <1% | 72 | $15.24 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 452 | $15.00 |
| 73140 | <1% | 39 | $13.60 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 661 | $10.16 |
| 84295 | <1% | 44 | $9.62 | |
| 69210 | <1% | 13 | $9.34 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,104 | $9.27 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 133 | $3.00 |
| 82272 | <1% | 29 | $2.88 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 307 | $0.56 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 49 | $0.22 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 13 | $0.20 |
| C1758 | Catheter, ureteral | 0% | 107 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 155 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 62 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 117 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 58 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 101 | $0.00 |
| 91300 | 0% | 15 | $0.00 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 59 | $0.00 |
| 87634 | 0% | 29 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 58 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 92 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 45 | $0.00 |
| 95852 | 0% | 99 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 102 | $0.00 |
| 87147 | 0% | 30 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 15 | $0.00 |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 24 | $0.00 |
| 96380 | 0% | 18 | $0.00 | |
| J7609 | Albuterol, inhalation solution, compounded product, administered through dme, unit dose, 1 mg | 0% | 13 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 24 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 13 | $0.00 |
| 96127 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, JONATHAN (PRESIDENT & CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Ira Davenport Memorial Hospital, INC. | Bath, NY | $4.69M |
| Arnot Ogden Medical Center | Elmira, NY | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.